BRPI0409068A - composições farmacêuticas para inibidores de protease viral de hepatite c. - Google Patents
composições farmacêuticas para inibidores de protease viral de hepatite c.Info
- Publication number
- BRPI0409068A BRPI0409068A BRPI0409068-3A BRPI0409068A BRPI0409068A BR PI0409068 A BRPI0409068 A BR PI0409068A BR PI0409068 A BRPI0409068 A BR PI0409068A BR PI0409068 A BRPI0409068 A BR PI0409068A
- Authority
- BR
- Brazil
- Prior art keywords
- viral protease
- pharmaceutical compositions
- protease inhibitors
- hepatitis
- pharmaceutically acceptable
- Prior art date
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010019799 Hepatitis viral Diseases 0.000 title 1
- 201000001862 viral hepatitis Diseases 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 3
- 208000005176 Hepatitis C Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSIçõES FARMACêUTICAS PARA INIBIDORES DE PROTEASE VIRAL DE HEPATITE C". A presente invenção refere-se composições farmacêuticas de inibidores de protease viral de hepatite C, e métodos de uso destas composições para inibição da replicação de vírus de hepatite C (HCV) e para o tratamento de uma infecção de HCV. Estas composições são sistemas baseados em lipídeo e compreendem o inibidor de protease viral de hepatite C junto com pelo menos uma amina farmaceuticamente aceitável, pelo menos uma base farmaceuticamente aceitável, pelo menos um óleo farmaceuticamente aceitável e, opcionalmente, um ou mais ingredientes adicionais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45976503P | 2003-04-02 | 2003-04-02 | |
| PCT/US2004/008837 WO2004093915A1 (en) | 2003-04-02 | 2004-03-23 | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409068A true BRPI0409068A (pt) | 2006-03-28 |
Family
ID=33310709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409068-3A BRPI0409068A (pt) | 2003-04-02 | 2004-03-23 | composições farmacêuticas para inibidores de protease viral de hepatite c. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7157424B2 (pt) |
| EP (1) | EP1613353A1 (pt) |
| JP (1) | JP2006522017A (pt) |
| KR (1) | KR20050108420A (pt) |
| CN (1) | CN100363055C (pt) |
| AR (1) | AR043795A1 (pt) |
| AU (1) | AU2004231538A1 (pt) |
| BR (1) | BRPI0409068A (pt) |
| CA (1) | CA2520886A1 (pt) |
| CO (1) | CO5640152A2 (pt) |
| EA (1) | EA010013B1 (pt) |
| EC (1) | ECSP056065A (pt) |
| HR (1) | HRP20050871A2 (pt) |
| MX (1) | MXPA05010338A (pt) |
| NO (1) | NO20055057L (pt) |
| NZ (1) | NZ543250A (pt) |
| PE (1) | PE20050013A1 (pt) |
| RS (1) | RS20050741A (pt) |
| TW (1) | TW200505484A (pt) |
| UA (1) | UA81028C2 (pt) |
| UY (1) | UY28250A1 (pt) |
| WO (1) | WO2004093915A1 (pt) |
| ZA (1) | ZA200506019B (pt) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| EP1673385B1 (en) * | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2005070955A1 (en) * | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2006242475B2 (en) * | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR057456A1 (es) * | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| EP2305696A3 (en) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US8278322B2 (en) * | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| EA200801050A1 (ru) * | 2005-10-11 | 2008-12-30 | Интермьюн, Инк. | Соединения и способы ингибирования репликации вирусного гепатита с |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US20070281884A1 (en) * | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
| US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| CA2667165A1 (en) * | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| CN101583372A (zh) | 2006-10-24 | 2009-11-18 | 默克公司 | Hcv ns3蛋白酶抑制剂 |
| US8138164B2 (en) * | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| JP5268927B2 (ja) * | 2006-10-27 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
| WO2008057208A2 (en) * | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8101595B2 (en) * | 2006-12-20 | 2012-01-24 | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA | Antiviral indoles |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0625349D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008137779A2 (en) * | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2686546A1 (en) * | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| AU2008277442A1 (en) * | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis C infections |
| CN101754974B (zh) | 2007-07-19 | 2016-02-03 | Msd意大利有限公司 | 作为抗病毒剂的大环化合物 |
| GB2451811A (en) | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
| CA2708047A1 (en) | 2007-12-06 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis c protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CA2714604A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Macrocyclic hcv ns3 protease inhibitors |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102014911A (zh) | 2008-04-28 | 2011-04-13 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| ES2392611T3 (es) * | 2008-07-22 | 2012-12-12 | Merck Sharp & Dohme Corp. | Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2011006631A (es) | 2008-12-19 | 2011-09-06 | Gilead Sciences Inc | Inhibidores de proteasa ns3 del virus hcv. |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| PE20120322A1 (es) * | 2009-07-07 | 2012-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| US20110312973A1 (en) * | 2010-03-10 | 2011-12-22 | Bernd Liepold | Solid compositions |
| WO2012083170A1 (en) * | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제 |
| WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
| US20120213855A1 (en) * | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012176149A1 (en) | 2011-06-23 | 2012-12-27 | Panmed Ltd. | Treatment of hepatitis c virus |
| US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) * | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN103965286B (zh) * | 2014-04-22 | 2017-11-03 | 南京安赛莱医药科技有限公司 | 丙型肝炎病毒(hcv)ns3蛋白酶抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4524367B2 (ja) | 1997-07-29 | 2010-08-18 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 自己乳化性処方形態の酸性親油性化合物用の医薬組成物 |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| EP1673385B1 (en) | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
-
2004
- 2004-03-23 RS YUP-2005/0741A patent/RS20050741A/sr unknown
- 2004-03-23 EA EA200501532A patent/EA010013B1/ru not_active IP Right Cessation
- 2004-03-23 BR BRPI0409068-3A patent/BRPI0409068A/pt not_active IP Right Cessation
- 2004-03-23 KR KR1020057018703A patent/KR20050108420A/ko not_active Withdrawn
- 2004-03-23 CA CA002520886A patent/CA2520886A1/en not_active Abandoned
- 2004-03-23 NZ NZ543250A patent/NZ543250A/en unknown
- 2004-03-23 US US10/807,023 patent/US7157424B2/en not_active Expired - Lifetime
- 2004-03-23 EP EP04759731A patent/EP1613353A1/en not_active Withdrawn
- 2004-03-23 MX MXPA05010338A patent/MXPA05010338A/es active IP Right Grant
- 2004-03-23 WO PCT/US2004/008837 patent/WO2004093915A1/en not_active Ceased
- 2004-03-23 HR HR20050871A patent/HRP20050871A2/xx not_active Application Discontinuation
- 2004-03-23 JP JP2006501244A patent/JP2006522017A/ja active Pending
- 2004-03-23 UA UAA200510334A patent/UA81028C2/uk unknown
- 2004-03-23 CN CNB2004800087739A patent/CN100363055C/zh not_active Expired - Fee Related
- 2004-03-23 AU AU2004231538A patent/AU2004231538A1/en not_active Abandoned
- 2004-03-31 UY UY28250A patent/UY28250A1/es not_active Application Discontinuation
- 2004-03-31 TW TW093108968A patent/TW200505484A/zh unknown
- 2004-03-31 AR ARP040101067A patent/AR043795A1/es not_active Application Discontinuation
- 2004-03-31 PE PE2004000340A patent/PE20050013A1/es not_active Application Discontinuation
-
2005
- 2005-07-27 ZA ZA200506019A patent/ZA200506019B/en unknown
- 2005-09-30 EC EC2005006065A patent/ECSP056065A/es unknown
- 2005-10-28 CO CO05110321A patent/CO5640152A2/es not_active Application Discontinuation
- 2005-10-31 NO NO20055057A patent/NO20055057L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2520886A1 (en) | 2004-11-04 |
| RS20050741A (sr) | 2007-06-04 |
| AR043795A1 (es) | 2005-08-10 |
| ZA200506019B (en) | 2006-07-26 |
| UA81028C2 (en) | 2007-11-26 |
| US20040229776A1 (en) | 2004-11-18 |
| US7157424B2 (en) | 2007-01-02 |
| NZ543250A (en) | 2008-12-24 |
| TW200505484A (en) | 2005-02-16 |
| CN100363055C (zh) | 2008-01-23 |
| MXPA05010338A (es) | 2005-11-17 |
| EA010013B1 (ru) | 2008-06-30 |
| WO2004093915A1 (en) | 2004-11-04 |
| AU2004231538A1 (en) | 2004-11-04 |
| UY28250A1 (es) | 2004-11-30 |
| HK1091130A1 (en) | 2007-01-12 |
| JP2006522017A (ja) | 2006-09-28 |
| PE20050013A1 (es) | 2005-03-01 |
| HRP20050871A2 (en) | 2006-10-31 |
| ECSP056065A (es) | 2006-01-27 |
| KR20050108420A (ko) | 2005-11-16 |
| CN1767856A (zh) | 2006-05-03 |
| EP1613353A1 (en) | 2006-01-11 |
| NO20055057L (no) | 2005-10-31 |
| EA200501532A1 (ru) | 2006-06-30 |
| CO5640152A2 (es) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307524A (pt) | Composição farmacêutica para inibidores de protease viral de hepatite c | |
| TW200505484A (en) | Pharmaceutical compositions for hepatitis C viral protease inhibitors | |
| MX2007004783A (es) | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. | |
| BR0112666A (pt) | Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c | |
| BRPI0516825A (pt) | inibição da protease ns3-ns4a do vìrus da hepatite c (vhc) | |
| BR9712544A (pt) | Inibidores de proteases de serina, particularmente protease ns3 do vìrus hapatite c | |
| BR0305259A (pt) | Inibidores de hcv ns5b polimerase | |
| PT1268519E (pt) | Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c | |
| BR0112540A (pt) | Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c | |
| BRPI0508217A (pt) | cetamidas com p4's cìclico como inibidores de ns3 serina protease de vìrus de hepatite c | |
| DK1066247T3 (da) | Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease | |
| BR0311132A (pt) | Inibidores do vìrus da hepatite c | |
| BR0306931A (pt) | Peptìdeos como inibidores de protease serina-ns3 do vìrus da hepatite c | |
| PL378107A1 (pl) | 1,2,4-triazyny hamujące HIV | |
| BR0206614A (pt) | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto | |
| NO20044897L (no) | Hepatitt C virus inhibitorer | |
| BR0305426A (pt) | Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos | |
| CY1109523T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv | |
| BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
| DK1569929T3 (da) | Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner | |
| BR0211289A (pt) | Derivados de dolastatina 10 | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| EA200600227A1 (ru) | Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| BR9916004A (pt) | Inibidores de proteinase c de pró-colágeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |